NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan's intravitreal dexamethasone implant cleared by NICE for use in the NHS for macular edema; survives comparison with intravitreal Avastin with equivocal data.
You may also be interested in...
U.K. Cost Watchdog Rejects Lucentis’ Extended Use In Eye Disease
NICE’s draft rejection of Lucentis for use in secondary ophthalmologic indications comes as competition looms from Eylea in key AMD setting
Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.
Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema
NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.